Santen Pharmaceutical Co., Ltd.
SNPHYOTCHealthcare● Active
$12.15
+$0.40(+3.38%)
Market Cap$3.9B
P/E Ratio—
52W High$12.68
52W Low$9.22
Santen Pharmaceutical Co., Ltd. (SNPHY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SNPHY · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
$0.31
Revenue
$0.52B
Est. $0.52B · -0.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
SNPHY reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2026 | May 11, 2026 | — | $0.31 | — | $0.52B | $0.52B | -0.8% |
| — Q1 FY2026 | Feb 4, 2026 | — | $0.16 | — | $0.47B | $0.49B | -3.0% |
| — Q4 FY2025 | Nov 5, 2025 | — | $0.16 | — | $0.47B | — | — |
| — Q3 FY2025 | Aug 8, 2025 | — | $0.12 | — | $0.47B | $0.50B | -5.8% |
| — Q2 FY2025 | May 13, 2025 | — | $0.18 | — | $0.53B | $0.50B | +7.2% |
| — Q1 FY2025 | Feb 6, 2025 | — | $0.16 | — | $0.49B | $0.53B | -8.4% |
| — Q4 FY2024 | Nov 7, 2024 | — | $0.16 | — | $0.48B | — | — |
| — Q3 FY2024 | Aug 6, 2024 | — | $0.18 | — | $0.47B | — | — |
Q2 FY2026
May 11, 2026
EPS Actual
$0.31
EPS Est.
—
EPS Surpr.
—
Revenue
$0.52B
Q1 FY2026
Feb 4, 2026
EPS Actual
$0.16
EPS Est.
—
EPS Surpr.
—
Revenue
$0.47B
Q4 FY2025
Nov 5, 2025
EPS Actual
$0.16
EPS Est.
—
EPS Surpr.
—
Revenue
$0.47B
Q3 FY2025
Aug 8, 2025
EPS Actual
$0.12
EPS Est.
—
EPS Surpr.
—
Revenue
$0.47B
Q2 FY2025
May 13, 2025
EPS Actual
$0.18
EPS Est.
—
EPS Surpr.
—
Revenue
$0.53B
Q1 FY2025
Feb 6, 2025
EPS Actual
$0.16
EPS Est.
—
EPS Surpr.
—
Revenue
$0.49B
Q4 FY2024
Nov 7, 2024
EPS Actual
$0.16
EPS Est.
—
EPS Surpr.
—
Revenue
$0.48B
Q3 FY2024
Aug 6, 2024
EPS Actual
$0.18
EPS Est.
—
EPS Surpr.
—
Revenue
$0.47B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $72.2B | $73.1B | $74.0B | 3 |
| Q2 FY2026 | $69.0B | $70.7B | $72.5B | 2 |
| Q1 FY2026 | $80.9B | $83.0B | $85.0B | 2 |
| Q4 FY2025 | $74.2B | $76.5B | $77.6B | 3 |
| Q3 FY2025 | $68.7B | $69.9B | $71.2B | 3 |
| Q2 FY2025 | $69.0B | $72.3B | $78.2B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 11, 2026 | — | $10.69 | $10.34 | -3.27% |
| — Q1 FY2026 | Feb 4, 2026 | — | $11.32 | $11.24 | -0.71% |
| — Q4 FY2025 | Nov 5, 2025 | — | $9.84 | $9.89 | +0.51% |
| — Q3 FY2025 | Aug 8, 2025 | — | $10.55 | $10.03 | -4.93% |
| — Q2 FY2025 | May 13, 2025 | — | $9.89 | $10.09 | +2.02% |
| — Q1 FY2025 | Feb 6, 2025 | — | $9.91 | $9.81 | -1.01% |
| — Q4 FY2024 | Nov 7, 2024 | — | $10.99 | $11.69 | +6.37% |
| — Q3 FY2024 | Aug 6, 2024 | — | $10.87 | $10.88 | +0.09% |
Q2 FY2026-3.27%
Report Date
May 11, 2026
EPS Beat/Miss
—
Price Before
$10.69
Price After
$10.34
Q1 FY2026-0.71%
Report Date
Feb 4, 2026
EPS Beat/Miss
—
Price Before
$11.32
Price After
$11.24
Q4 FY2025+0.51%
Report Date
Nov 5, 2025
EPS Beat/Miss
—
Price Before
$9.84
Price After
$9.89
Q3 FY2025-4.93%
Report Date
Aug 8, 2025
EPS Beat/Miss
—
Price Before
$10.55
Price After
$10.03
Q2 FY2025+2.02%
Report Date
May 13, 2025
EPS Beat/Miss
—
Price Before
$9.89
Price After
$10.09
Q1 FY2025-1.01%
Report Date
Feb 6, 2025
EPS Beat/Miss
—
Price Before
$9.91
Price After
$9.81
Q4 FY2024+6.37%
Report Date
Nov 7, 2024
EPS Beat/Miss
—
Price Before
$10.99
Price After
$11.69
Q3 FY2024+0.09%
Report Date
Aug 6, 2024
EPS Beat/Miss
—
Price Before
$10.87
Price After
$10.88
Beat Rate0 / 8 quarters
Largest Move+6.37% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SNPHY ends December
Santen Pharmaceutical Co., Ltd. (SNPHY) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $0.31 (in line with the analyst consensus of —). The next SNPHY earnings date is expected around September 1, 2026.
Each quarter, investors track SNPHY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SNPHY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SNPHY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SNPHY earnings · 4 questionsSanten Pharmaceutical Co., Ltd.'s next earnings report is expected around September 1, 2026. SNPHY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SNPHY historically reports after market close (AMC).
SNPHY earnings datewhen is SNPHY earningsSNPHY next earnings datewhen does SNPHY report earningsSNPHY earnings calendar
▸ Source: FMP · Santen Pharmaceutical Co., Ltd. SEC filings · US GAAP · Santen Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026